Gomis Sellés, ElíasMaldonado, AntonioGaztañaga, MirenVera, VictoriaAjulia, OdileSancho, GemmaSiva, ShankarLópez Campos, FernandoCouñago Lorenzo, Felipe2025-10-062025-10-062025Gomis-Sellés, E., Maldonado, A., Gaztañaga, M., Vera, V., Ajulia, O., Sancho, G., Siva, S., Lopez-Campos, F., & Couñago, F. (2025). Impact of psma-pet/ct on radiotherapy decisions: Is there a clinical benefit? Cancers, 17(8), 1350. https://doi.org/10.3390/cancers170813502072-6694https://hdl.handle.net/11268/16358Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) has emerged as a game-changing imaging modality in prostate cancer, offering superior sensitivity and specificity compared to conventional imaging techniques. Its increasing adoption has significantly influenced radiotherapy decision-making, yet its true clinical impact remains under investigation. This narrative review explores the role of PSMA-PET/CT in guiding radiotherapy decisions across different clinical scenarios, from primary treatment planning to biochemical recurrence and oligometastatic disease. We assess its impact on target delineation, treatment modifications, and overall patient management while addressing existing knowledge gaps.engAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Neoplasias de la PróstataRadioterapiaAndrógenosjournal article10.3390/cancers17081350open accessCáncerHombreTratamiento médicoGoal 3: Ensure healthy lives and promote well-being for all at all ages